Designing for Success: Navigating Early Phase Translational Medicine Studies to Expedite Patient Inclusion
- Practical strategies for successful IVD and CDx regulatory submissions and clinical studies
- How the EU IVDR Article 5(5) Health Institution Exemption can provide speed and flexibility for pharma-led precision medicine programmes
- Lessons learned and case studies from ARC’s collaborations in translational and precision medicine trials